Sinopharm Accord(000028) 华福证券·2025-04-10 13:15Investment Rating - The investment rating for the company is "Buy" [10] Core Views - The company's 2024 performance was impacted by impairment losses, but it is expected to achieve recovery growth in 2025 [6] - The company reported a revenue of 74.378 billion yuan in 2024, a decrease of 1.46%, and a net profit attributable to shareholders of 642 million yuan, down 59.83% [2][3] - The report highlights the company's focus on high-quality development and innovation in its distribution and retail segments [4][5] Financial Performance - The company recognized a total impairment of 1.094 billion yuan, which significantly affected its net profit [3] - The distribution segment achieved a revenue of 53 billion yuan, an increase of 1.98%, while the retail segment generated 22.357 billion yuan, a decrease of 8.41% [4] - The gross profit margin for 2024 was 11.09%, down 0.9 percentage points, and the net profit margin was 0.86%, down 1.26 percentage points [5] Profit Forecast and Investment Suggestions - The profit forecasts for 2025-2027 have been revised downwards, with expected net profits of 1.34 billion yuan, 1.46 billion yuan, and 1.59 billion yuan respectively [6] - The company is positioned as a leading pharmaceutical wholesale and retail platform, with significant potential for profit release in its retail business [6]